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 Practicing physicians must frequently 
extrapolate evidence from clinical trials 
to their own patients who would not 
have been eligible for the trial. A common 
exclusion is chronic kidney disease 
(CKD). All of the major studies of 
bisphosphonates have excluded patients 
with recognized kidney disease, present-
ing a challenge when the patients have low 
bone density and a high fracture risk, 
whose patients have low bone density and 
high fracture risk. In patients with CKD, 
the safety and effi  cacy could be diff erent 
from those in other patients. 
 Safety is the fi rst concern. In the large 
randomized trials of oral bisphosphonates 
there were no signifi cant side eff ects. With 
use, reports of esophagitis and bone 
pain have emerged as common adverse 
effects, and osteonecrosis of the jaw, 
atypical femur fractures, and esophageal 
cancer are rare events associated with 
these drugs. Acute renal failure has been 
reported with intravenous bisphospho-
nates, especially when given with rapid 
infusion and frequent doses to patients 
with malignancy. 1 With the annual infu-
sions given to osteoporotic patients, there 
were only modest changes in creatinine in 
0.4 % of placebo-treated patients and 1.3 % 
of patients treated with zoledronic acid. 2 
In older patients with a hip fracture, an 
increase in serum creatinine of more than 
0.5  mg / dl was seen in a similar percentage 
of patients in both the placebo group 
(5.6 % ) and the zoledronic acid group 
(6.2 % ). 3 Sporadic cases of acute kidney 
diseases have been reported, and the 
kidney biopsies show tubular injury with 
low NA   +   , K   +   -ATPase expression. 4 
 Th e mechanism of toxicity is uncertain 
but may be related to known properties of 
the drugs. Th e amino-bisphosphonates 
bind tightly to bone mineral. While 
resorbing bone, osteoclasts ingest the 
bisphosphonates, which inhibit farnesyl 
pyrophosphate synthase. Th is results in 
inhibition of prenylation of small GTPases, 
which are necessary for maintenance of 
the cytoskeleton and ruffl  ed border. It also 
results in accumulation of the precursor 
isopentenyl pyrophosphate, which causes 
an acute phase reaction aft er an intrave-
nous administration. 5 Th e bisphospho-
nates are internalized by the proximal 
tubular cells as well as the osteoclasts, and 
they also may have disrupted cytoskeletal 
architecture leading to renal damage. 
 In clinical trials of oral bisphosphonates, 
acute renal failure was not increased. Th e 
new report by Shih  et al. 6 (this issue) 
found no increased incidence of acute 
kidney injury in a large population-based 
survey of elderly patients treated with oral 
bisphosphonates following a hospital 
admission for a fracture. Th is is a reassur-
ing report about one important aspect of 
safety. Only 5 % of the study population 
had stage 4 CKD. Th us, these safety results 
may not apply to most of the patients 
followed by nephrologists. With our cur-
rent understanding of the renal toxicity of 
bisphosphonates, it seems likely that the 
oral formulations would be safer than the 
intravenous ones in patients with CKD, 
but there will be uncertainty without a 
head-to-head comparison. 
 Other safety issues must be considered 
in this group of patients. Th e bisphospho-
nates bind strongly to mineralized tissue 
that normally is exclusively in the skele-
ton. Soft -tissue calcifi cations can also bind 
bisphosphonates, as seen with bone-scan-
ning agents containing bisphosphonates. 
In patients with ordinary osteoporosis, the 
nonskeletal tissues have short and low 
exposure to the drugs, because half of the 
drug is deposited into the skeleton and the 
rest excreted in an hour. In patients with 
late stages of CKD, the bisphosphonates 
are not excreted as rapidly, and they may 
concentrate within soft -tissue calcifi ca-
tions. One important and unexplored 
question is whether there are any adverse 
eff ects related to bisphosphonate deposi-
tion in these nonskeletal sites. 
 Vascular calcifications are a serious 
problem in patients with CKD – mineral 
and bone disorder (CKD-MBD). The 
interactions between bisphosphonates 
and vascular calcifi cations are complex 
and are not well understood. Etidronate 
inhibits mineralization and has been 
shown to improve vascular calcifi cations 
in some animal models and small patient 
studies. Th is inhibition is dose-dependent 
and is not seen with the vastly smaller 
doses used with the newer generation of 
amino-bisphosphonates. Studies in sub-
jects with osteoporosis as well as those 
with late stages of CKD have not shown 
any signifi cant diff erence in the extent of 
calcifi cations comparing alendronate or 
ibandronate with placebo. 7,8 Other 
adverse cardiovascular eff ects have not 
been consistently seen in patients with 
ordinary osteoporosis, although there 
have been some studies with higher inci-
dence of atrial fi brillation. A review by the 
US Food and Drug Administration did 
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not fi nd a signifi cant increase in arrhyth-
mias. In the largest registration trial for 
alendronate, the event rates for myocar-
dial infarction were not publicly released. 
A retrospective cohort study included 
9604 women with stages 3 – 4 CKD who 
did not have a previous serious cardio-
vascular event. Th ey were followed for 3.9 
years to ascertain mortality and rate of 
serious cardiac events. In 3234 women 
who had been exposed to bisphospho-
nates, the all-cause mortality was signifi -
cantly better than in the patients who had 
not taken bisphosphonates. However, 
there was no benefi t for cardiovascular 
events. Notably, in those patients who ini-
tially had some cardiac disease, the hazard 
ratios were 1.20 for death and 1.24 for a 
serious cardiovascular end point. 9 
 A theoretical concern about bisphos-
phonate toxicity in CKD patients relates 
to the low bone turnover that is a direct 
eff ect of the drugs. Several studies have 
found a correlation between low bone 
turnover and vascular calcifi cation. It is 
postulated that the mineralizing bone sur-
face buff ers the extracellular phosphate 
concentration. With a low mineralizing 
surface, phosphate loads cannot be depo-
sited into the bone and instead increase 
the serum concentrations. This can 
lead to a vicious cycle ( Figure 1 ) that is 
one potential pathway in a network of 
factors that regulate mineral metabolism. 
Th e phosphate stimulates diff erentiation 
of the vascular smooth muscle cells into 
osteoblasts. Th is is also promoted by Wnt 
signaling and is inhibited by moderate 
levels of 1,25-vitamin D. Th e osteoblasts 
then form bone inside the vascular walls. 
New studies have found that these cells 
also secrete inhibitors of the Wnt signal-
ing pathway, possibly as a protective 
mechanism. However, the circulating 
inhibitors, such as frizzled-related protein, 
can further inhibit bone formation. 10 
Bisphosphonates could exacerbate the 
process. On the other hand, high turnover 
can also increase serum phosphate by 
directly releasing it from the bone, and in 
this case the bisphosphonates could be 
helpful. Th ese complex interactions need 
further basic and translational research. 
 Even if the bisphosphonates are safe in 
CKD patients, they should not be used 
unless they are eff ective, as determined for 
meaningful outcomes such as fracture or 
bone pain. Bone density is an imperfect 
surrogate outcome. Fluoride causes the 
greatest increase in bone density, but we 
don ’ t use it, because the patients had more 
fractures and the bone quality was 
impaired. In patients with ordinary osteo-
porosis, bisphosphonates are eff ective at 
reducing incidence of clinical fractures, 
including hip and spine fractures, as 
shown in multiple randomized clinical 
trials that have enrolled more than 30,000 
subjects. Furthermore, observations from 
clinical practice have also shown reduced 
fracture rates with bisphosphonates. 
However, at best only half of the fractures 
are prevented. Subjects without existing 
vertebral fractures whose hip bone density 
T-score was better than  – 2.5 did not have 
fewer non-vertebral fractures with alen-
dronate. Limited  post hoc data suggest 
that the fracture rate was decreased only 
in subjects whose baseline bone turnover 
was high. 11 Th is makes sense, because the 
bisphosphonates reduce bone resorption, 
so those with low bone resorption are less 
likely to benefi t. 
 Th e evidence for patients with CKD is 
much less extensive. Th e large randomized 
trials excluded those with known renal 
failure, or with abnormal parathyroid hor-
mone, calcium, or alkaline phosphatase. 
 Post hoc studies on the remaining subjects 
with an estimated glomerular fi ltration 
rate (eGFR) lower than 60 have shown 
that the fracture reduction was similar to 
rates in subjects with a normal eGFR. Th is 
is reassuring, because many patients with 
osteoporosis also have mild CKD, since 
both conditions increase with aging. 
 In patients with later-stage CKD, parti-
cularly when laboratory abnormalities 
start to appear, there is no evidence about 
the effi  cacy of bisphosphonates in terms 
of fracture reduction. Bone density in 
these patients with CKD-MBD is typically 
normal at the spine and low in the cortical 
bone, measured at the hip and radius. 
Bone turnover is variable, but recent 
studies fi nd that the majority of patients 
have low turnover. Th e largest and most 
recent study of alendronate in stage 4 – 5 
CKD included 49 subjects and showed a 
small increase in bone density at the spine 
but no signifi cant increase in the hip. 8 
 In summary, the new study by Shih 
 et al. 6 is reassuring to patients with osteo-
porosis and mild CKD, in whom there is 
reasonable evidence of effi  cacy, and these 
patients should be treated to prevent crip-
pling fractures. However, important ques-
tions remain about the safety and effi  cacy 
of bisphosphonates in those with more 
advanced kidney disease. In theory, the 
bone strength could increase with these 
drugs in select patients with high bone 
resorption despite optimal control of 
parathyroid hormone, but this cannot be 
recommended until more data become 
available. 
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 Figure 1  |  Interactions between low bone turnover and vascular calcifications in chronic 
kidney disease. Vascular smooth muscle cells differentiate into osteoblasts under the influence of 
vitamin D and Wnt signaling. The osteoblasts secrete frizzled-related protein (sFRP), which blocks 
the Wnt signaling but also causes low bone formation. Bisphosphonates could exacerbate this. 
The low bone formation leads to increased serum phosphate, which stimulates the changes in the 
smooth muscle cells. 
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 Mononuclear phagocyte 
depletion strategies in models 
of acute kidney disease: what 
are they trying to tell us ? 
 Matthew D.  Griffin 1 
 Mononuclear phagocytes (macrophages, dendritic cells, and 
monocytes) play a complex role in kidney disease. Techniques 
for selectively depleting them in rodents have made important 
contributions but have also generated some contradictory results. 
Ferenbach  et al. report that two widely used mononuclear phagocyte 
depletion techniques differentially affect early severity of renal 
ischemia / reperfusion injury and provide evidence that this may 
be due to a residual, protective subset that persists in the kidney 
after one of the two techniques. 
 Kidney International (2012)  82, 835 – 837.  doi: 10.1038/ki.2012.164 
 Th e healthy rodent or human kidney con-
tains a plentiful population of bone mar-
row-derived myeloid cells with phenotypic 
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and functional characteristics that overlap 
with those of classical macrophages and 
dendritic cells. 1,2 Th e fact that these cells, 
located predominantly in the interstitium, 
have been variously referred to as renal 
macrophages and renal dendritic cells in 
the literature may, to some degree, have 
hampered progress in broadly understand-
ing their biological roles. For this reason, 
the (older) term mononuclear phagocyte 
(MoPh) has more recently been used as a 
broader descriptor. 1,2 Multicolor flow 
cytometry studies in mice suggest that 
resident renal MoPhs (rMoPhs) consist of 
at least two major histocompatibility com-
plex class II-expressing sub-populations, a 
predominant (  >  90 % ), CD11b   +   subset and 
a less abundant, CD11b   −   CD103   +   subset, 
although the functional signifi cance of 
each remains poorly defined. 1 During 
health, these cells have a slow turnover rate 
(2 – 8 weeks) with replacements derived 
from the common macrophage and 
dendritic precursor (MDP) in the bone 
marrow via circulating monocytes and / or 
a pre-dendritic-cell precursor. 1,2 In the 
setting of acute or chronic renal injury, 
the resident rMoPhs are supplemented by 
an infl ux of monocytes from the circula-
tion, which themselves undergo activation 
and are capable of differentiating into 
functionally heterogeneous infl ammatory 
macrophages and dendritic cells. 1 
 Given that the full functional spectrum 
of the mononuclear phagocytic system 
(which encompasses monocytes, macro-
phages, dendritic cells, and cells of inter-
mediate phenotype) includes intense 
proinfl ammatory responses, microbial and 
cell killing, antigen uptake and presenta-
tion to the T-cell compartment, counter-
regulation of innate and adaptive immune 
responses, promotion of tissue healing, and 
regeneration and induction of fi brosis, it 
is not surprising that there is very high 
interest in better understanding and mani-
pulating this system in the context of renal 
diseases. 1 
 For the kidney, as for other organs, the 
most commonly addressed issue regarding 
the mononuclear phagocytic system and 
its individual cellular components has 
been their role in the severity of and recov-
ery from acute injury of diverse causes. In 
addition to its unequivocal clinical rele-
vance, the experimental setting of acute 
kidney injury (AKI) allows for the 
responses of both resident and infi ltrating 
rMoPhs to be determined from a  ‘ standing 
start ’ and to be tracked over time during 
the course of a relatively predictable series 
of events. However, as the complexity of 
the mononuclear phagocytic system has 
revealed itself over the past decade, it has 
become clear that the veracity of conclu-
sions drawn from studies of rMoPhs 
during AKI is only as good as the tools 
